2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska, PG Conaghan… - Annals of the …, 2023 - ard.bmj.com
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodriguez-Carrio, A Burska… - Annals of the …, 2023 - diva-portal.org
Background: Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
[PDF][PDF] 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska, PG Conaghan… - Annals of the …, 2023 - ard.bmj.com
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska… - Annals of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
[PDF][PDF] 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska, PG Conaghan, WA Dik… - 2023 - researchgate.net
ABSTRACT Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic
and musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
and musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska… - Annals of the …, 2023 - search.proquest.com
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
J Rodríguez-Carrio, A Burska… - Annals of the …, 2023 - europepmc.org
Type I interferons (IFN-Is) play a role in a broad range of rheumatic and musculoskeletal
diseases (RMDs), and compelling evidence suggests that their measurement could have …
diseases (RMDs), and compelling evidence suggests that their measurement could have …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska… - Annals of the …, 2023 - research.nu.edu.kz
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
[PDF][PDF] 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez Carrio, A Burska… - Annals of the …, 2023 - digibuo.uniovi.es
ABSTRACT Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic
and musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
and musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska… - Annals of the …, 2023 - search.proquest.com
Background Type I interferons (IFN-Is) play a role in a broad range of rheumatic and
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …
musculoskeletal diseases (RMDs), and compelling evidence suggests that their …